

**Musculoskeletal Australia  
Pharmaceutical Benefits Advisory Committee (PBAC)**



MUSCULOSKELETAL  
AUSTRALIA

**Musculoskeletal relevant drugs for consideration at the November 2020 PBAC Meeting**

Below is a list of the musculoskeletal relevant drugs for consideration by the PBAC at their next meeting in November 2020. Consumer comments about any of these drugs must be received by the PBAC **by 5pm (AEST) on Wednesday 7 October 2020**.

If you wish to submit your comments to PBAC with the help of the MSK staff, please respond to the questions in the last column of the table below via email **by no later than 5pm (AEST) on Thursday, 1 October 2020**. Please send your email responses to [info@msk.org.au](mailto:info@msk.org.au)

<b>Drug name</b>	<b>Musculoskeletal condition/s</b> (What is the drug used to treat?)	<b>Purpose of the submission</b> (Nature of the request by the sponsor or drug company)	<b>If you wish to make a comment about these requests via MSK, please respond to the following questions</b>
FILGOTINIB	Rheumatoid arthritis (RA)	Gilead Sciences Pty Ltd is requesting that this drug be approved in tablet form (two different strengths) for the treatment of severe active rheumatoid arthritis. The brand name is Jyseleca®	<ol style="list-style-type: none"> <li>1) How does having rheumatoid arthritis affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the benefits (or additional benefits) of having this drug available?</li> <li>4) Are there any reasons why you think this drug should not be approved?</li> </ol>
GUSELKUMAB	Psoriatic arthritis (PsA)	Janssen-Cilag Pty Ltd is requesting that this drug be available as an injection in single use pre-filled syringe and single use pre-filled pen form for the treatment of adult patients with severe psoriatic arthritis who have had an inadequate response to methotrexate and sulfasalazine or leflunomide. The brand name is Tremfya®	<ol style="list-style-type: none"> <li>1) How does having psoriatic arthritis affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the benefits (or additional benefits) of having this drug available?</li> <li>4) Are there any reasons why you think this drug should not be approved?</li> </ol>

<b>Drug name</b>	<b>Musculoskeletal condition/s</b> (What is the drug used to treat?)	<b>Purpose of the submission</b> (Nature of the request by the sponsor or drug company)	<b>If you wish to make a comment about these requests via MSK, please respond to the following questions</b>
INFLIXIMAB	Rheumatoid arthritis (RA) Ankylosing spondylitis (AS) Psoriatic arthritis (PsA)	Celltrion Healthcare Australia Pty Ltd is requesting that this drug be available as an injection in single use pre-filled syringe and single use pre-filled pen form under the same conditions as infliximab powder for I.V. infusion. The brand name is Remsima®	<ol style="list-style-type: none"> <li>1) How does having rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the benefits (or additional benefits) of having this drug available?</li> <li>4) Are there any reasons why you think this drug should not be approved?</li> </ol>
SECUKINUMAB	Non-radiographic axial spondyloarthritis (nr-axSpA)	Novartis Pharmaceuticals Australia Pty Ltd is requesting that this drug be available as an injection in a pre-filled pen form. The brand name is Cosentyx®	<ol style="list-style-type: none"> <li>1) How does having non-radiographic axial spondyloarthritis affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the benefits (or additional benefits) of having this drug available?</li> <li>4) Are there any reasons why you think this drug should not be approved?</li> </ol>